In 2016, the Technopolis “Khimgrad” is celebrating its 10th anniversary. On September 8th, as part of the events dedicated to the celebration, there have been an inaugural opening of the three new facilities on the territory of the site, as well as an exhibition of products of Technopolis residents. The President of the Republic of Tatarstan Rustam Minnikhanov and the representatives of federal and regional authorities have attended the events.
The laboratory and the industrial complex has been launched, which will develop and produce drugs with biopolymers, micro- and nanoparticles, as well as the strong medicine for the treatment of cancer, HIV and drugs for transplant, according to RIA Novosti.
The new complex is built by the Innovative technology park “Idea” with the support of the government of Tatarstan and the Fund for Infrastructure and Educational Programs “Rosnano”. The complex is equipped with the modern automated production line, which does not require personnels’ direct contact with drugs.
“Today, in the presence of the President of Tatarstan, a solemn transfer of laboratory and industrial complex and the land under it from the technology park “Idea” and nanotechnology center on the implementation of the project “Drug delivery systems based on nanotechnology” to the company “Nanofarma Development”, stated in the press service of the Head of the Republic of Tatarstan.
In March 2010, the technology park “Idea” application won the competition for the selection of nanotechnology centers projects, which was conducted by the SC “RUSNANO”. As part of the project of this center, the pharmaceutical company “Izvarino Pharma” and technology park “Idea” have developed an anchor project – the laboratory and industrial complex “Nanofarma Development”. In December 2015, the technology park “Idea” has decided to withdraw from the project and the company “Izvarino Pharma” has acquired its share in the “Nanofarma Development”. “Nanofarma Development” is a part of nanotechnology cluster in Tatarstan and is a key one in the field of pharmaceuticals.
According to the technology park “Idea”, investment in the project amounted to 559.5 million rubles, up to 600 thousand packages a year of hormonal and potent drugs will be produced here. The company’s revenue in 2021 should be around 780 million rubles.
As being said by the Director General of LLC “Nanofarma Development” Orest Ibragimov, the installed equipment made by insulator design allows drugs to treat the HIV-related infections, cancer drugs, preparations for transplantation of organs and tissues. According to him, all these drugs and technologies were developed “from scratch” by the research group of “Nanofarma Development”, which proved their complete reproducibility in relation to imported drugs. The company developed its own patents on many formulas, showing that these drugs are not only as good as the foreign developments but are also created using more modern technologies.
Today, the lab team has already registered three drugs that are included in the list of vital and essential medicines. It includes “Tsivalgan” (valganciclovir) – a drug for the treatment of the cytomegalovirus retinitis on the background of AIDS, as well as the cytomegalovirus infection following organ transplantation in patients at risk, “Imatinib” – a drug for the treatment of leukemia, “Tacrolimus” – a drug that has imunosuppressive effects and is used in the treatment of and the prevention of rejection of the liver, kidneys, heart allografts.